Back to articles
Comparative guide · 6 min read

Citicoline vs Alpha-GPC — two cholinergic compounds compared

Updated 2026-05-13 · Reviewed by SupplementScore editors · No sponsorships

Citicoline (CDP-choline) and Alpha-GPC (alpha-glycerophosphocholine) are the two main "premium" cholinergic supplements — both deliver choline to the brain more efficiently than basic choline bitartrate and both raise membrane phospholipid synthesis substrates. Citicoline has the stronger clinical-trial evidence base (vascular cognitive impairment, post-stroke recovery, age-related memory complaints, glaucoma). Alpha-GPC has older European clinical data plus a niche acute-performance signal (mental and athletic), but it carries a recent prospective-cohort observational signal of association with incident stroke that warrants attention.

Quick verdict

GoalBetter choiceWhy
Age-related memory complaints in older adultsCiticolineMultiple RCTs and IDEAL/IDEALE trials support 500 mg/day for memory and attention in older adults.
Post-stroke cognitive recoveryCiticolineLong history of European/Spanish trial use; mixed but supportive evidence.
Acute cognitive performance / pre-workout focusAlpha-GPCFaster onset, more cholinergic "punch" per dose; small acute-performance trials.
Power output / strength athleticsAlpha-GPC (small evidence)Small trials show modest improvement in peak power; effect size is uncertain.
Long-term cardiovascular safety profileCiticolineAlpha-GPC has a recent cohort signal for incident stroke; citicoline doesn't.
Cost per doseSimilarBoth run $15–35/month at typical doses.

How they actually work

Citicoline — feeds the Kennedy pathway

Cytidine-5'-diphosphocholine (CDP-choline / citicoline) is hydrolysed to cytidine and choline, which cross the blood-brain barrier independently and reassemble centrally. The cytidine pathway feeds into the synthesis of phosphatidylcholine (and indirectly other membrane phospholipids) via the Kennedy pathway. The choline portion contributes to acetylcholine synthesis. The dual contribution — membrane phospholipid plus neurotransmitter precursor — distinguishes citicoline mechanistically from simpler choline forms.

Alpha-GPC — direct choline delivery

Alpha-glycerophosphocholine is a small phospholipid metabolite that crosses the blood-brain barrier intact and is metabolised centrally to produce choline (~40% by weight) directly available for acetylcholine synthesis and phosphatidylcholine production. Per gram, Alpha-GPC delivers more central choline than CDP-choline. Onset is faster (60–90 min vs 2–4 h for citicoline).

Cognition in older adults — citicoline's clearest case

The IDEALE study (Cotroneo 2013) and several other Italian/Spanish trials show 500 mg/day citicoline improves cognitive measures in older adults with mild vascular cognitive impairment. The CITIRIVAD and CITICOLAGE-Italia open-label studies extended the signal into mild Alzheimer's-pattern impairment when added to acetylcholinesterase inhibitors. Quality of trials is variable but the direction is consistent.

Acute performance — Alpha-GPC's niche

Small acute-dose trials at 250–600 mg Alpha-GPC have shown modest improvements in reaction time, growth-hormone response to exercise, and lower-body power output 60–90 min post-dose. Effect sizes are small; replication is limited. This makes Alpha-GPC the more commonly used cholinergic in "pre-workout" and "stim stack" products.

Alpha-GPC cardiovascular signal. A 2021 retrospective analysis of South Korean health insurance data (Lee et al, JAMA Network Open) found that long-term Alpha-GPC users had higher 10-year incident stroke rates than matched non-users. This is observational data with confounding limitations (users with cognitive complaints may have higher baseline cerebrovascular risk), but it warrants caution — particularly for chronic high-dose use in users with vascular risk factors. Citicoline does not carry this signal.

Eye conditions — citicoline's secondary niche

Several small RCTs show citicoline (oral or intramuscular) modestly slows visual field decline in glaucoma; the mechanism is hypothesised to involve neuroprotection of retinal ganglion cells. Effect sizes are modest; this is reasonable adjunct, not a substitute for IOP-lowering therapy.

Dose, form, and timing

Citicoline: 250–500 mg/day in 1–2 doses, with breakfast or lunch (mild activation in some users — avoid late evening). Brand names include Cognizin (Kyowa Hakko, well-studied) and various generics. Allow 4–8 weeks for cognitive effect.

Alpha-GPC: 300–600 mg/day. For acute use, 250–600 mg taken 60–90 min before a high-demand event. For chronic use, 300–400 mg/day with meals.

Safety profile

Citicoline: well-tolerated. Rare GI upset, headache, insomnia (if dosed late). No significant drug interactions established. Long human history including pharmaceutical use in Europe.

Alpha-GPC: well-tolerated short-term. The 2021 cohort stroke signal warrants caution for long-term high-dose use, particularly in users with hypertension, AFib, prior TIA/stroke, or familial vascular disease. Reasonable to avoid chronic high-dose Alpha-GPC in these populations until prospective trials clarify; short-term acute use likely lower-risk.

Practical rule. For chronic supplementation aimed at cognition or age-related memory complaints, citicoline 500 mg/day is the better-evidenced and safer-profiled choice. Reserve Alpha-GPC for acute pre-event use (300–600 mg, 60–90 min before) where the cholinergic "punch" is needed; consider avoiding chronic high-dose Alpha-GPC in users with vascular risk factors.

When neither is the right answer

For diagnosed dementia, the trial-grade interventions are acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, and (where appropriate) anti-amyloid antibody therapies — under neurology care. Cholinergic supplements may have small adjunct value but don't replace these. For ADHD focus, evidence-based prescription stimulants substantially outperform cholinergic supplements.

Who should pick each

Pick citicoline if: chronic supplementation for cognition or age-related memory complaints, vascular risk factors present, you want the better long-term safety profile.

Pick Alpha-GPC if: acute "pre-event" pre-workout or pre-cognitive-task focus, no chronic vascular risk concerns, short-term use only.

What we'd actually buy

For chronic cognitive support in a 60+ adult: citicoline 500 mg with breakfast for an 8-week trial, paired with omega-3 (EPA/DHA), B-vitamins, vitamin D adequacy, and aerobic exercise. For occasional pre-event acute use in a younger adult with no vascular concerns: Alpha-GPC 300 mg taken 60–90 min before a demanding cognitive task.

Sources

Read more: